Overview
Semaglutide (Ozempic, Wegovy) is a GLP-1 receptor agonist that changed obesity medicine forever. In the landmark STEP trials, participants lost an average of 15% of body weight over 68 weeks — results previously achievable only through bariatric surgery.
It is a legitimate, FDA-approved medication, not a research chemical — which also means it requires a prescription and medical supervision.
How It Works
GLP-1 (glucagon-like peptide-1) is a gut hormone released after eating. Semaglutide mimics it with a week-long half-life, acting on three fronts: it slows gastric emptying so food sits longer, it enhances glucose-dependent insulin secretion, and — most importantly — it acts directly on appetite centers in the brainstem and hypothalamus.
The food noise effect
Users consistently describe the silencing of food noise — the constant background thoughts about eating. This central appetite effect, not the stomach slowing, appears to drive most of the weight loss.
Key Benefits
Weight loss — ~15% average body weight reduction in trials; the most effective approved obesity drug of its era.
Cardiovascular protection — the SELECT trial showed a 20% reduction in major cardiac events in people with established heart disease.
Blood sugar control — its original indication; excellent HbA1c reductions in type 2 diabetes.
Emerging areas — trials ongoing for addiction, Alzheimer disease and fatty liver disease.
Side Effects & Considerations
Nausea, vomiting, diarrhea and constipation are common, especially during dose escalation — most improve with time. The labeled warnings include pancreatitis, gallbladder disease and a thyroid C-cell tumor signal seen in rodents (relevance to humans unproven, but it is contraindicated with personal or family history of medullary thyroid carcinoma or MEN2).
Muscle loss and rebound
Roughly 25-40% of weight lost is lean mass — resistance training and high protein intake are non-negotiable companions. Stopping the drug typically regains most of the weight within a year; this is a chronic therapy, not a course. Grey-market semaglutide from peptide vendors is unregulated, often underdosed or contaminated, and legally dubious — the real thing exists and is the sane route.
Dosage protocols
| Protocol | Dosage | Frequency | Duration | Notes |
|---|---|---|---|---|
| Approved titration (Wegovy) | 0.25 mg weekly, escalating every 4 weeks | Once weekly subcutaneous | Chronic therapy | Titration: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg. Prescription only — follow the prescribing physician. |
Warnings
Prescription medication. Contraindicated with personal/family history of medullary thyroid carcinoma or MEN2. Expect lean mass loss without resistance training. Weight regains on discontinuation.